A Phase 1/2 First-in-human Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Malignant Tumors
Latest Information Update: 11 Oct 2024
At a glance
- Drugs BMS 986288 (Primary) ; Nivolumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Bristol-Myers Squibb
Most Recent Events
- 07 Oct 2024 Status changed from active, no longer recruiting to completed.
- 30 Jul 2024 Planned primary completion date changed from 28 Jun 2024 to 31 Oct 2024.
- 16 May 2024 Planned primary completion date changed from 14 Apr 2024 to 28 Jun 2024.